On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication,
study design (controlled study, open trial, case report etc.) and other criteria.
|Title||Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study.|
|Author(s)||Lahat A, Lang A, Ben-Horin S.|
|Journal, Volume, Issue||Digestion. 2012;85(1):1-8.|
|Major outcome(s)||Significant improvement of several symptoms.|
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) patients suffer from
significant morbidity and diminished life quality. The plant cannabis is
beneficial in various gastrointestinal diseases, stimulating appetite and causing
weight gain. Our aims were to assess whether treatment with inhaled cannabis
improves quality of life, disease activity and promotes weight gain in these
METHODS: Patients with long-standing IBD who were prescribed cannabis treatment
were included. Two quality of life questionnaires and disease activity indexes
were performed, and patient's body weight was measured before cannabis initiation
and after 3 months' treatment.
RESULTS: Thirteen patients were included. After 3 months' treatment, patients
reported improvement in general health perception (p = 0.001), social functioning
(p = 0.0002), ability to work (p = 0.0005), physical pain (p = 0.004) and
depression (p = 0.007). A schematic scale of health perception showed an improved
score from 4.1 ± 1.43 to 7 ± 1.42 (p = 0.0002). Patients had a weight gain of 4.3
± 2 kg during treatment (range 2-8; p = 0.0002) and an average rise in BMI of 1.4
± 0.61 (range 0.8-2.7; p = 0.002). The average Harvey-Bradshaw index was reduced
from 11.36 ± 3.17 to 5.72 ± 2.68 (p = 0.001).
CONCLUSIONS: Three months' treatment with inhaled cannabis improves quality of
life measurements, disease activity index, and causes weight gain and rise in BMI
in long-standing IBD patients.
|Participants||13 patients with inflammatory bowel disease|
|Type of publication||Medical journal|
|Address of author(s)||Department of Gastroenterology, Chaim Sheba Medical Center affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. firstname.lastname@example.org|